$DVLT

Wilson Wendy sold $10K of DVLT

Wilson Wendy sold 25,856 shares of Datavault AI Inc. (DVLT) at $0.39 on 2026-06-11.

Original reporting
SEC EDGAR · Wilson Wendy
Published Jun 12, 2026, 8:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DVLT
Bearish
medium confidence
Mentioned
$DVLT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVLTBearishLow
01

Why it matters

The disclosure updates the insider ownership record and may influence short-term sentiment, but it does not introduce new operating or financial information.

02

Market read

Traders may monitor DVLT for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

The article doesn’t state motivations, tax/option exercises, or whether other insiders are buying; impact may be muted versus broader tape/liquidity effects.

Relevance 3/10Novelty 8/10Timing: filed 2026-06-12 (sale dated 2026-06-11)

Background

SEC Form 4 insider transaction disclosure for Datavault AI Inc. (DVLT).

Company-level read

Ticker impact

$DVLTBearishMedium confidence
Context

Datavault AI director Wilson Wendy filed a Form 4 selling 25,856 shares of DVLT at $0.3900 on 2026-06-11.

Expected impact

Likely limited/short-lived impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a director sale with no 10b5-1 plan and provides transaction details, but it does not disclose company performance, contracts, or regulatory outcomes.

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Director sales can be pre-planned for liquidity or diversification; absence of a 10b5-1 plan doesn’t necessarily imply negative outlook.

Key entities

  • Datavault AI Inc.

    Company whose shares were sold by a director via an open-market transaction.

  • Wilson Wendy

    Director who sold 25,856 shares of DVLT at $0.3900/share.

Related articles

$DVLTMed

Datavault AI Hit With Securities Lawsuit

Datavault AI Inc. (NASDAQ: DVLT) faces a new securities class action, according to DJS Law Group, alleging the company misled investors about operations, partnerships, and growth prospects. The proposed class period is Sept. 4, 2024 to Oct. 30, 2025. The claims stem largely from a Wolfpack Research report that preceded a ~19% one-day share drop. Lead plaintiff deadline is Oct. 5, 2026.

$DVLTMed

Pomerantz Law Firm Announces the Filing of a Class Action Against Datavault AI Inc. and Certain Officers - DVLT

Pomerantz LLP said it filed a securities class action against Datavault AI Inc. (NASDAQ: DVLT) and certain officers in the Eastern District of Pennsylvania, covering purchases from Sept. 4, 2024 to Oct. 30, 2025. The suit alleges misleading statements about partnerships, trading activity, and compliance. After a Wolfpack Research report on Oct. 31, 2025, DVLT shares fell 19.44% to $2.03.

$DVLTMed

Datavault AI Expands Data Driven Outcome Healthcare

Datavault AI (NASDAQ:DVLT) said it amended its definitive agreement with DataMeds AI (NASDAQ:MEDS) to expand a PharmacyChain blockchain technology licensing relationship into unencumbered commercial healthcare, healthspan and wellness uses. Datavault AI will receive common shares worth about 19.9% of DataMeds’ stock at closing, replacing preferred shares for tax optimization.

$MEDSMed

DataMEDS AI, Inc.: DataMeds AI Expands License with DataVault AI for Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License

DataMeds AI (NASDAQ:MEDS) said it amended its licensing agreement with Datavault AI (NASDAQ:DVLT) to expand PharmacyChain blockchain-related licensing from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses. The deal is tied to a pending multi-party combination and includes DVLT receiving common shares worth about 19.9% of MEDS at closing.